NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=156717&from=3 CLASS PERIOD: Aug ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Red Cat Holdings, Inc. (NASDAQ: RCAT). Shareholders who purchased shares of RCAT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/red-cat-holdings-inc-loss-submission-form/?id=156712&from=3  CLASS PERIOD: ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=156711&from=3 CLASS PERIOD: Ju ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF). Shareholders who purchased shares of WOOF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/petco-loss-submission-form/?id=156710&from=3  CLASS PERIOD ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156709&from=3 CLASS PERIOD: June 22, 2 ...

Core Viewpoint - The Schall Law Firm is investigating Gilead Sciences, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its HIV treatment trials [1][2]. Group 1: Investigation Details - The investigation centers on whether Gilead issued false or misleading statements or failed to disclose critical information to investors [2]. - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns, specifically a decrease in CD4+ T-cell and absolute lymphocyte counts in some trial participants [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to reach out for assistance [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

There’s a great deal you can learn about one of America’s most valuable and beloved companies from a lawsuit about pants. 🔗 https://t.co/HGvRP6jGVw https://t.co/qFpILLEPWY ...

Core Viewpoint - Investors have until July 22, 2025, to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for failing to disclose material information during the class period from November 3, 2022, to April 30, 2025 [1][3] Company Information - Organon & Co. is facing lawsuits for allegedly violating federal securities laws by not disclosing important information during the specified class period [3] - The company announced a significant reduction in its dividend payout from $0.28 to $0.02 on March 10, 2025, which contradicted previous assurances to investors about maintaining the dividend [4] Financial Impact - Following the announcement of the dividend cut, Organon's share price dropped over 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4] Legal Proceedings - The first filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322, with a subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanding the class period [5]

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly providing misleading information regarding its expected revenue and earnings during the Class Period from December 12, 2024, to June 30, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided investors with overly positive statements about enrollment and morbidity rates while concealing adverse facts about the company's true performance [5]. - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Group 1: Company Background - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp to receive various administrative and IT support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4] Group 3: Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-Spin-Off business model [5]